Jinjing Liu

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 6

Top Topics

Cerebrospinal Fluid

Diffuse Large B Cell Lymphoma

Rheumatoid Arthritis Patients

Top Venues

Annals of the rheumatic diseases

Therapeutic advances in musculoskeletal disease

Proceedings of the National Academy of Sciences of the United States of America

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Wenjie Zheng, Xiao-Man Wang, Jinjing Liu, Xin Yu, Lu Li, Heping Wang, Jijun Yu, Xiaoya Pei, Chaoran Li, Zhimian Wang, Menghao Zhang, Xiaofeng Zeng, Fengchun Zhang, Chenfei Wang, Ketian Li, Hou-Zao Chen
Single-cell analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet's disease. Proceedings of the National Academy of Sciences of the United States of America 119 (26) (2022)
Jinjing Liu, Jimei Tian, Zhimian Wang, Li Wang, Can Huang, Jiaxin Zhou, Xiao-Feng Zeng, Yan Zhao, Wenjie Zheng
Secukinumab in the treatment of parenchymal neuro-Behçet's syndrome. Rheumatology (Oxford, England) 61 (9) (2022)
Jinjing Liu, Chan Zhao, Wenjie Zheng
Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou et al. Annals of the rheumatic diseases (2021)
Jinjing Liu, Yunxia Hou, Luxi Sun, Chaoran Li, Lu Li, Yan Zhao, Xiaofeng Zeng, Fengchun Zhang, Wenjie Zheng
A pilot study of tofacitinib for refractory Behçet's syndrome. Annals of the rheumatic diseases 79 (11) (2020)
Jinjing Liu, Dong Yan, Zhimian Wang, Yunjiao Yang, Shangzhu Zhang, Di Wu, Lingyi Peng, Zhichun Liu, Wenjie Zheng
Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review. Therapeutic advances in musculoskeletal disease 12 (2020)
Zhe Chen, Shangzhu Zhang, Li Wang, Yunyun Fei, Min Shen, Huanwen Wu, Jinjing Liu, Wenjie Zheng
Anaplastic large cell lymphoma in a patient with MAGIC syndrome: a case and review of the literature. Clinical rheumatology 40 (5) (2020)